Title : Oral idasanutlin in patients with polycythemia vera.

Pub. Date : 2019 Aug 8

PMID : 31167802






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Therefore, we performed an investigator-initiated phase 1 trial of the oral MDM2 antagonist idasanutlin (RG7388; Roche) in patients with high-risk PV/ET for whom at least 1 prior therapy had failed. RG7388 MDM2 proto-oncogene Homo sapiens